Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia.

Chang JE, Medlin SC, Kahl BS, Longo WL, Williams EC, Lionberger J, Kim K, Kim J, Esterberg E, Juckett MB.

Leuk Lymphoma. 2008 Dec;49(12):2298-307. doi: 10.1080/10428190802517732.

2.

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM.

Cancer. 2014 Dec 1;120(23):3660-8. doi: 10.1002/cncr.28930. Epub 2014 Jul 17.

4.

Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers.

Alacacioglu I, Medeni SS, Ozsan GH, Payzin B, Sevindik OG, Acar C, Katgi A, Ozdemirkan F, Piskin O, Ozcan MA, Undar B, Demirkan F.

Chemotherapy. 2014;60(4):219-23. doi: 10.1159/000375258. Epub 2015 Apr 3.

PMID:
25871894
5.

Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.

Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM.

Am J Hematol. 2016 Aug;91(8):819-23. doi: 10.1002/ajh.24419. Epub 2016 Jun 30.

6.

High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.

Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, Venn NC, van den Berg H, de Bont ES, Maarten Egeler R, Hoogerbrugge PM, Kaspers GJ, Bierings MB, van der Schoot E, van Dongen J, Law T, Cross S, Mueller H, de Haas V, Haber M, Révész T, Alvaro F, Suppiah R, Norris MD, Pieters R.

Leukemia. 2013 Jul;27(7):1497-503. doi: 10.1038/leu.2013.44. Epub 2013 Feb 14.

PMID:
23407458
7.

The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.

Güneş AM, Oren H, Baytan B, Bengoa SY, Evim MS, Gözmen S, Tüfekçi O, Karapınar TH, Irken G.

Ann Hematol. 2014 Oct;93(10):1677-84. doi: 10.1007/s00277-014-2106-0. Epub 2014 May 27.

PMID:
24863691
8.

High hyperdiploid acute lymphoblastic leukemia (ALL)-A 25-year population-based survey of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.

Reismüller B, Steiner M, Pichler H, Dworzak M, Urban C, Meister B, Schmitt K, Pötschger U, König M, Mann G, Haas OA, Attarbaschi A; Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.

Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26327. Epub 2016 Nov 2.

PMID:
27804199
9.

Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II.

Aricò M, Valsecchi MG, Conter V, Rizzari C, Pession A, Messina C, Barisone E, Poggi V, De Rossi G, Locatelli F, Micalizzi MC, Basso G, Masera G.

Blood. 2002 Jul 15;100(2):420-6.

10.

A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.

Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR, et al.

Blood. 1995 Apr 15;85(8):2025-37.

11.

Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.

Tzortzatou-Stathopoulou F, Papadopoulou AL, Moschovi M, Botsonis A, Tsangaris GT.

J Pediatr Hematol Oncol. 2001 Dec;23(9):591-7. Review.

PMID:
11902303
12.

Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect.

Chiu EK, Chan LC, Liang R, Lie A, Kwong YL, Todd D, Chan TK.

Leukemia. 1994 Sep;8(9):1469-73.

PMID:
8090027
13.

Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group.

Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Uckun FM, Bleyer WA.

Cancer. 1998 Feb 1;82(3):600-12.

PMID:
9452280
14.
15.
16.
17.

Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.

Hunault-Berger M, Milpied N, Bernard M, Jouet JP, Delain M, Desablens B, Sadoun A, Guilhot F, Casassus P, Ifrah N.

Leukemia. 2001 Jun;15(6):898-902.

PMID:
11417474
18.

Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia.

Linker C, Damon L, Ries C, Navarro W.

J Clin Oncol. 2002 May 15;20(10):2464-71.

PMID:
12011123
19.

Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients.

Chen YC, Ho CL, Kao WY, Hwang JM, Sheu LF, Chao TY.

Ann Hematol. 2001 Nov;80(11):647-52.

PMID:
11757723
20.

Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.

Ribera JM, Oriol A, Sanz MA, Tormo M, Fernández-Abellán P, del Potro E, Abella E, Bueno J, Parody R, Bastida P, Grande C, Heras I, Bethencourt C, Feliu E, Ortega JJ.

J Clin Oncol. 2008 Apr 10;26(11):1843-9. doi: 10.1200/JCO.2007.13.7265.

PMID:
18398150

Supplemental Content

Support Center